Pull to refresh
Logo
Scientists identify body's natural brake on inflammation

Scientists identify body's natural brake on inflammation

New Capabilities

Fat-derived molecules keep harmful immune cells in check, human trial shows

Today: ScienceDaily reports on the hidden inflammation switch

Overview

Updated 1 hour ago

Inflammation is supposed to stop once the threat passes. University College London researchers found the body's built-in brake for that process, and a drug can press it. In a controlled human trial, the drug sped up pain resolution and cut immune cells tied to chronic disease.

The brake is a family of fat-derived molecules called epoxy-oxylipins. They stop intermediate monocytes, immune cells linked to rheumatoid arthritis, lupus, and cardiovascular disease, from accumulating. Blocking the enzyme soluble epoxide hydrolase (sEH), which normally breaks these molecules down, made the brake stronger.

Why it matters

If soluble epoxide hydrolase inhibitors hold up in chronic disease trials, millions with rheumatoid arthritis and heart disease could gain a safer, targeted treatment.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

48
Volunteers in the controlled trial
24 received the drug GSK2256294, 24 received placebo across two dosing arms.
2
Dosing strategies tested
Drug was given 2 hours before inflammation began and 4 hours after it started.
12,13-EpOME
Main epoxy-oxylipin identified
Suppresses the p38 mitogen-activated protein kinase (p38 MAPK) pathway driving monocyte transformation.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

January 2026 September 2026

3 events Latest: Today
  1. ScienceDaily reports on the hidden inflammation switch

    Today Reporting

    Renewed coverage highlights the mechanism and its potential for chronic inflammatory disease treatments.

  2. Inflammation brake study published

    Publication

    Nature Communications publishes the UCL study identifying epoxy-oxylipins as immune regulators.

  3. Controlled human trial completes

    Clinical Research

    48 volunteers finish the two-arm study; drug group shows faster pain resolution and fewer intermediate monocytes.

Scenarios

1

sEH inhibitor enters Phase 2 trial for rheumatoid arthritis

Likely Resolves by End of 2028

Discussed by: UCL study authors, Dr. Bracken

The drug GSK2256294 already has human safety data from the acute inflammation trial. Researchers have proposed testing it alongside existing rheumatoid arthritis medications. A Phase 2 trial would measure whether boosting epoxy-oxylipins slows joint damage over months of treatment.

2

Chronic disease studies fail to replicate acute results

Possible Resolves by Q2 2029

Discussed by: Morning Overview and other outlets noting study limitations

The trial used a single injection of dead E. coli to trigger temporary inflammation. Rheumatoid arthritis involves feedback loops, tissue remodeling, and immune memory that a short stimulus cannot replicate. If the mechanism does not hold in disease models, the drug remains a research tool rather than a treatment.

3

sEH inhibitor trials expand to cardiovascular disease and lupus

Possible Resolves by Q2 2029

Discussed by: Study authors, whose findings note applications beyond arthritis

Intermediate monocytes are elevated in cardiovascular disease, lupus, and other conditions. If early chronic disease trials show promise, sponsors could register trials in these indications. That would signal that the resolution mechanism is broadly applicable.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2000s

Resolvins discovery (early 2000s)

Charles Serhan's lab at Harvard found lipid molecules called resolvins that actively shut down inflammation. This showed the body resolves inflammation through active chemical signals rather than passive decay.

Then

Resolvins became a research field and led to synthetic resolvin analogs in development.

Now

Established the concept of pro-resolving mediators, the intellectual foundation the UCL study builds on.

Why this matters now

Epoxy-oxylipins belong to the same family of lipid mediators and add a new, druggable target to the resolution toolkit.

1940s-1950s

Corticosteroids for inflammation (1940s-1950s)

Cortisone was first used to treat rheumatoid arthritis in 1948. It suppressed inflammation broadly but caused severe side effects with long-term use, including bone loss and immune suppression.

Then

Corticosteroids became a standard treatment despite side effects.

Now

The search for targeted anti-inflammatory drugs that avoid broad immune suppression has driven decades of research.

Why this matters now

sEH inhibitors aim to amplify a natural resolution pathway rather than suppress the immune system wholesale, a different approach from corticosteroids.

1990s

TNF inhibitors for rheumatoid arthritis (1990s)

Researchers found tumor necrosis factor (TNF) drives joint destruction in rheumatoid arthritis. Drugs like infliximab and etanercept block TNF and transformed treatment of the disease.

Then

TNF inhibitors became first-line biologics for rheumatoid arthritis and related conditions.

Now

They proved that precisely targeting inflammatory proteins can control chronic disease in ways broad immunosuppressants could not.

Why this matters now

sEH inhibitors would similarly target a specific molecular pathway, but instead of blocking a driver of inflammation, they amplify the body's own stop signal.

Sources

(8)